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Alzheimer’s disease is a neurodegenerative condition characterized by an accumulation of toxic amyloid beta- (Aβ-)peptides in the
braincausingprogressiveneuronaldeath.Aβ-peptidesareproducedbyaspartylproteinase-mediatedcleavageofthelargeramyloid
precursor protein (APP). In contrast to this detrimental “amyloidogenic” form of proteolysis, a range of zinc metalloproteinases
can process APP via an alternative “nonamyloidogenic” pathway in which the protein is cleaved within its Aβ region thereby
precluding the formation of intact Aβ-peptides. In addition, other members of the zinc metalloproteinase family can degrade
preformed Aβ-peptides. As such, the zinc metalloproteinases, collectively, are key to downregulating Aβ generation and enhancing
its degradation. It is the role of zinc metalloproteinases in this “positive side of proteolysis in Alzheimer’s disease” that is discussed
in the current paper.
1.Introduction
Alzheimer’s disease (AD) is the leading form of dementia
in the elderly, accounting for some two-thirds of all cases
and exhibiting a prevalence of 5% in individuals older
than 65 years. The disease is clinically characterized by
a progressive cognitive impairment, including impaired
decision making, orientation and judgement often accompa-
nied, in the later stages, by psychobehavioural disturbances
and language impairment. AD was originally described in
1906 by the German psychiatrist and neuropathologist,
Alois Alzheimer, but it was his coworker, Emil Kraepelin
who ﬁrst coined the term “Alzheimer’s disease” [1]. What
Alzheimer described were what we now know as the
two major pathological hallmarks in the brains of AD-
aﬄicted individuals, amyloid (also known as senile) plaques
and neuroﬁbrillary tangles (NFTs) [2]. At the molecular
level, NFTs are composed of tau, a microtubule-associated
protein which, in AD, becomes hyperphosphorylated and
forms insoluble intracellular ﬁbrils [3]. Amyloid plaques,
on the other hand, are extracellular structures composed
of 38–43 amino acid peptides called amyloid beta (Aβ)-
peptides.
Although it is important to appreciate that AD is a
multifactorialdisease[4],akeytheoryastodiseasecausation
is that of the “amyloid cascade hypothesis” whereby Aβ-
peptides are the leading cause of toxicity to neurons [5].
The initial version of the hypothesis proposed that mature
amyloid ﬁbrils and plaques in the brain were responsible
for the observed neurotoxicity, but more recent incarnations
point towards the earlier stage, smaller soluble Aβ aggregates
being the primary cause of AD [6, 7]. Whatever the case, it is
clear that an increase in Aβ in the brain has a role to play in
AD pathogenesis.
Proteolysis dictates both the level of Aβ-peptides gen-
erated in the ﬁrst instance and the rate at which they are
degraded in the second. As such, a ﬁne balancing act of
proteolytic enzyme activities is at play in the brain keeping
Aβ levels in check. Although a range of proteinase classes
are involved directly or indirectly in the metabolism of
Aβ, most notably it is the zinc metalloproteinases that are
key to downregulating Aβ generation and enhancing its2 Biochemistry Research International
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Figure 1: Proteolysis of the amyloid precursor protein (APP).
APP can be cleaved by two alternative proteolytic pathways, the
amyloidogenic and nonamyloidogenic pathways. It is the balance
betweenthesetwopathwayswhichdictatesthelevelsofAβ-peptides
generated. KPI: Kunitz-type serine proteinase inhibitor domain;
OX-2: OX-2 domain; Aβ: amyloid beta; AICD: APP intracellular
domain.
degradation. It is the role of zinc metalloproteinases in this
“positive side of proteolysis in Alzheimer’s disease” that will
be discussed in the current paper.
2. Aβ-PeptideGeneration:ABalancing
Act between Nonamyloidogenic and
Amyloidogenic Proteolysis
Aβ-peptides are generated from a much larger precursor
protein, the amyloid precursor protein (APP), a ubiquitous
type I cell surface protein of as yet unknown physiological
function (Figure 1)[ 8]. The protein exists in multiple
isoforms as a result of alternative splicing of the 19 exons
encoded by the APP gene [9]. Exon 7 encodes for a 57-amino
acid region with considerable homology to a Kunitz-type
serine protease inhibitor (KPI) and is present in the larger
APP770 and APP751 isoforms, but absent from the smaller
APP695 protein.
The APP holoprotein can be proteolytically degraded
via an amyloidogenic pathway (Figure 1 a n dr e v i e w e di n
[10]) which involves initial cleavage by β-secretase (β-site
APP-cleaving enzyme 1; BACE1) to generate a soluble N-
terminal fragment termed sAPPβ along with a C-terminal
membrane-associated fragment (CTF) of 99 amino acids.
The C99 fragment is then further processed by a γ-secretase
complex producing the Aβ-peptides and the APP intracellu-
lar domain (AICD) [11]. Alternatively, APP can be processed
via a nonamyloidogenic route involving α-secretase cleavage
withintheAβ domain (reviewedin[12]).Thislattercleavage
occurs on the C-terminal side of Lys687 (APP770 numbering)
[13]andprecludesAβ-peptideformation,generatinginstead
a soluble APP ectodomain (sAPPα) along with a CTF of 83
amino acids (C83) (Figure 1).
3. ZincMetalloproteinasesin
the Prevention of Aβ Generation
The α-secretase-mediated nonamyloidogenic processing of
APP (Figure 1) represents a positive side of proteolysis in
AD in that it precludes formation of intact Aβ-peptides,
that is, there is a reciprocal relationship between nonamy-
loidogenic and amyloidogenic APP processing. Skovronsky
et al. [14] demonstrated that the activation of α-secretase
APP processing using phorbol esters in CHO cells stably
transfected with APP695 l e dt oar e d u c t i o ni nb o t hs A P P β
and Aβ production. At the in vivo level, the overexpression
of α-secretase activity in APP ([V717I]) transgenic mice
increased sAPPα generation with a concomitant reduction
in the formation of Aβ-peptides [15]. Proteolysis of APP
by α-secretases may also be considered a positive event
in that the sAPPα generated enhances the proliferation of
both nonneuronal and neuronal precursor cells [16–18],
stimulates neurite extension in immortalized neuronal cell
lines [19], modulates transmission at the synapse, and is
neuroprotective against ischemic, excitotoxic, and traumatic
brain injuries [20–24]. In vivo, the intracerebral injection of
sAPPα has been shown to enhance memory performance in
adult rats [25], and a truncated APP deletion variant cor-
responding to sAPPα has been shown to rescue anatomical,
behavioural, and electrophysiological abnormalities in APP-
deﬁcient mice [26] further underlining the physiological
importance of sAPPα generation.
Given the positive aspects of nonamyloidogenic APP
processing,theidentityoftheα-secretasewasofgreatinterest
to Alzheimer’s researchers. The ﬁrst clue in this respect
came when it was demonstrated that the α-secretase was
an integral membrane proteinase with its preference for the
Lys687-Leu688 peptide bond of APP being dictated more
by the proximity of the bond to the membrane than the
absolute amino acid speciﬁcity of the cleavage site [27, 28].
Using a range of class-speciﬁc proteinase inhibitors, it was
subsequently demonstrated that only the zinc chelator, 1,10-
phenanthroline, caused signiﬁcant inhibition of APP release
from crude membrane preparations in a cell-free system
[29] suggesting for the ﬁrst time that one or more zinc
metalloproteinases constituted the α-secretase activity. A
number of groups later reported that the active site-directed
zinc chelating compounds batimastat and TAPI-2 (Figure 2)
inhibited the release of sAPPα into the conditioned media of
a variety of cell lines [29–31].
A range of studies demonstrated that the zinc metal-
loproteinase activity responsible for generating sAPPα was
similar to that responsible for proteolytically “shedding” a
number of other substrate proteins from the cell surface.
For example, Parvathy et al. [30] compared the shedding
of APP to that of the angiotensin-converting enzyme (ACE;
EC 3.4.15.1) demonstrating that the release of both proteins
from transfected IMR-32 cells was inhibited by the hydrox-
amic acid-based compounds batimastat, marimastat, andBiochemistry Research International 3
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Figure 2: Structures of hydroxamic acid-based zinc metalloproteinase inhibitors.
BB2116 (Figure 2)w i t hI C 50 values in the low micromolar
range. In addition, Parkin et al. [32] demonstrated that a
range of hydroxamic acid-based compounds failed to dis-
criminate between the proteinases responsible for shedding
APP and the cellular form of the human prion protein, and
it has subsequently been demonstrated that both proteins
are indeed shed by the same enzyme [33]. Indeed it has
become apparent that the α-secretase activity is constituted
by one or more members of the ADAM (a disintegrin and
metalloproteinase) family of zinc metalloproteinases now
known to be responsible for shedding a multitude of cell
surface integral membrane proteins (reviewed in [34]).
3.1. The ADAMs Family of Zinc Metalloproteinases as
APP α-Secretases. The a disintegrin and metalloproteinases
(ADAMs) are zinc metalloproteinases belonging to the
metzincin super family. They are type I transmembrane
glycoproteins that constitute a family of some forty members
[34] which have a common modular ectodomain structure
consisting of an N-terminal prodomain, a catalytic domain,
a disintegrin domain, and a cysteine-rich domain (Figure 3).
The ADAM prodomain appears to be essential for protein
maturation maintaining the metalloproteinase site of the
newly synthesized protein in an inactive conformation
by way of a cysteine switch mechanism [35, 36] until
the domain is cleaved by prohormone convertases (PCs)
such as furin and PC7 [15, 35, 37, 38]. Furthermore this
domain seems to be essential for the correct folding of at
least two ADAM family members (ADAM10 and 17) as
its deletion resulted in catalytically inactive forms of the
proteins [35, 39]; in the case of ADAM10, catalytic activity
of the enzyme could be rescued by cotransfection of the
inactive construct with one encoding the prodomain alone
[35].
The prodomain is followed by a region which, in seven-
teenoftheknownADAMs,containstheconsensussequence,
HEXGHXXGXXHD, predicted to be the catalytic site of an
active zinc metalloproteinase [34]. This catalytic domain is
followed by the disintegrin domain, a 60–90-amino acid
residue stretch bearing limited sequence homology to the
disintegrin proteins isolated from snake venom and which
participates in various cell-cell adhesion events [40–45].
Finally, the cytosolic domains of the ADAMs are involved in
the binding of a wide range of adaptor proteins which may
inﬂuence maturation, traﬃcking, or proteolytic activity of
the enzymes [46].
It is becoming increasingly apparent that the α-se-
cretase activity is constituted by more than one ADAM
family member and that the proﬁle of these zinc-dependent4 Biochemistry Research International
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Figure 4: The involvement of zinc metalloproteinases in Aβ
metabolism. A range of ADAMs (10, 17, 9, 8, 19, and 33) have been
implicated in the nonamyloidogenic processing of APP to generate
sAPPα and C83, although the evidence for the latter four enzymes
having a direct physiological role in this respect is limited. ADAMs
9 and 15 are capable of cleaving ADAM10 and may be indirectly
involved in the activation of the nonamyloidogenic pathway in
this respect. Nardilysin also indirectly activates nonamyloidogenic
processing of APP via an activation of ADAMs 9, 10, and 17.
IDE, NEP, ECE-1, ECE-2, MMPs, GCPII and, possibly, ACE are
involved directly in the degradation of Aβ, and a potential role for
catalytically active ADAMs in the degradation of Aβ remains to be
elucidated.
APP-cleaving enzymes diﬀers considerably between diﬀerent
cell lines.
3.1.1. ADAM10. ADAM10 (EC 3.4.24.81) was ﬁrst identiﬁed
in 1989 as a peptide sequence puriﬁed from bovine brain
myelin membrane preparations and referred to as MADM
(Mammalian Disintegrin Metalloprotease) [47]. Following
cloning, the ﬁrst catalytic activity assigned to the enzyme
was its ability to degrade myelin basic protein (MBP) [48].
Like other ADAM family members, ADAM10 has a modular
ectodomain structure and is synthesized as an inactive
zymogen being activated only after enzymatic removal of
its prodomain [35]. In fact the recombinant ADAM10
prodomain puriﬁed from E. coli is a potent and selective
inhibitor of the enzyme in vitro [49]. The catalytic domain
of ADAM10 contains the zinc-binding consensus motif,
HEXGHXXGXXHD, whilst glycosylation sites containing
high-mannose and complex N-glycans are located both in
the catalytic and disintegrin domains [50]. Furthermore, an
N439 mutation at the N-glycosylation site of the enzyme
has been shown to increase the susceptibility of ADAM10 to
proteolytic degradation [50].
T h eg e n el o c u sf o rA D A M 1 0i nh u m a n si so nc h r o -
mosome 15 (15q21.3–q23) and chromosome 9 in mice
[51, 52], and both sequences are approximately 160kb in
length. The core promoter region in the human gene has
been identiﬁed by deletion analysis as nucleotides −508 to
−300bp which represents a TATA-less promoter containing
functional binding sites for USF, Sp1, and retinoic acid
receptors [53, 54]. In fact, the NAD-dependant deacetylase
SIRT1 directly activates transcription of the ADAM10 gene
possiblyviathedeacetylationandcoactivationoftheretinoic
acid receptor beta [55].
Given the fact that the original reported substrate for
ADAM10 (MBP) is a cytosolic protein and ADAM10 itself
is a type I membrane protein, it is unlikely that this
substrateisoneofphysiologicalrelevance.However,itisnow
known that the zinc metalloproteinase activity of ADAM10
is responsible for proteolytically shedding more than forty
integral membrane substrates from the cell surface including
growth factors (e.g., betacellulin and epidermal growth
factor), adhesion proteins (e.g., L1), other proteinases (e.g.,
BACE1),andarangeofothersubstratesincludingthehuman
prion protein [33] along with the Notch receptor and one of
its ligands, Delta [56].
Although it is now known that quite a range of ADAMs
may constitute the α-secretase activity, it is undoubtedly
ADAM10 that has sparked most research interest as an APP
cleaving enzyme. Lammich et al. [57] ﬁrst demonstrated that
bovine ADAM10 overexpressed in HEK cells enhanced the
basalcleavageofAPP.Theauthorsfurtherdemonstratedthat
APP cleaving activity stimulated by treatment of the cells
with phorbol ester (regulated cleavage) was also enhanced
by ADAM10 suggesting that the enzyme had a role in
both basal and regulated APP proteolysis. In addition, a
dominant negative form of ADAM10 with a point muta-
tion in the active site (E384A) inhibited the endogenous
α-secretase activity in HEK cells [57]. Furin-deﬁcient LoVo
c e l l sw h i c ha r ed e v o i do fr e g u l a t e dα-secretase activity
have also been used to demonstrate that overexpression
of ADAM10 enhanced the basal production of sAPPα
[38].
The involvement of ADAM10 in the zinc metallopro-
teinase-mediated cleavage of APP is also supported by
studiesusingsyntheticpeptidesubstrates.An18-merpeptide
spanning the α-secretase cleavage site was cleaved by puriﬁed
bovine kidney ADAM10 at the physiologically relevant α-
secretase cleavage site (Lys16-Leu17 of the Aβ region) [57].
Intriguingly, the insertion of a naturally occurring APP
mutation associated with cerebral haemorrhages due to
amyloid angiopathy (A21G) [58] into a similar synthetic
peptide substrate resulted in cleavage by ADAM10 at a
slower rate than the wild-type sequence peptide. Finally,
Amour et al. [59] demonstrated that an 11-mer peptideBiochemistry Research International 5
spanning the α-secretase cleavage site was cleaved by a
recombinant soluble form of the human ADAM10 catalytic
domain.
The in vitro cleavage of synthetic peptide substrates by
an enzyme can often bear limited parallels to the cleavage of
full-length physiological protein substrates. Unfortunately,
the study of ADAM10-mediated APP cleavage in vivo was,
for some time, limited by the embryonic and perinatal
lethality of ADAM10 knockout mice [60]. However, in
2004, human APP overexpressing mice were crossed with
ADAM10 transgenic animals, and the resultant progeny
demonstrated enhanced production of sAPPα in their brains
with a concomitant reduction of Aβ [15]. In contrast, the
crossing of a dominant-negative ADAM10 mutant mouse
with an APP transgenic animal had the opposite eﬀect,
inhibiting α-secretase cleavage of APP with a slight increase
in Aβ production. These studies clearly demonstrated that
the zinc metalloproteinase activity of ADAM10 was capable
of competing for APP in vivo with enzymes of the amyloido-
genic pathway.
A number of groups have demonstrated a link between
ADAM10 traﬃcking and maturation, and the zinc metallo-
proteinase activity responsible for the generation of sAPPα.
TheoverexpressionofPC7andfurininHEKcellstransfected
with ADAM10 resulted in a greater increase in sAPPα
production than when either enzyme was transfected into
cells expressing only endogenous ADAM10 [35] suggest-
ing that it was the removal speciﬁcally of the ADAM10
prodomain and subsequent activation of the enzyme that
correlated with the level of α- s e c r e t a s ea c t i v i t y .T h em a t u -
ration of ADAM10 can also be chemically manipulated so
as to increase sAPPαproduction. Epigallocatechin-3-gallate
(EGCG), a constituent of green tea, increased levels of the
mature 60kDa form of ADAM10 via a mechanism of action
speciﬁc to ADAM10 (the increase in sAPPα production
brought about by EGCG was only impaired in cells treated
with ADAM10 siRNA and not those treated with siRNA
targeted to ADAMs 9 and 17) [61]. The acetylcholinesterase
inhibitor, donepezil, also concomitantly increased sAPPα
production and the amount of mature ADAM10 in the
membrane fraction of SH-SY5Y cells, an eﬀect which could
be prevented by pretreatment of the cells with tunicamycin
or brefeldin suggesting a mechanism of action involving
the traﬃcking/maturation of the ADAM10 protein [62].
Finally, it seems that other proteins required for the traf-
ﬁcking of ADAM10 can aﬀect sAPPα production. Marcello
et al. [63] demonstrated that synapse-associated protein-
97 (SAP97), a protein involved in dynamic traﬃcking of
proteinstotheexcitorysynapse,wasresponsiblefordirecting
ADAM10 to the postsynaptic membrane via a direct inter-
action through its Src homology 3 domain. The authors
more recently reported [64] that ADAM10 contains an
arginine-rich ((723)RRR) sequence in its cytosolic domain
responsible for retaining the protein in the endoplasmic
reticulum (ER) and that, when the sequence was mutated,
protein exit from the ER occurred. However, SAP97 was not
thought to be involved in regulating this ER exit suggesting
the role of alternative protein binding partners in this
event.
3.1.2. ADAM17. ADAM17 (EC 3.4.24.86) was originally
identiﬁed as the proteinase responsible for shedding the
inﬂammatory cytokine tumour necrosis factor (TNF)-α
fromitsmembrane-associatedprecursorTNF[65,66]andis,
therefore, alternatively referred to as tumour necrosis factor-
α converting enzyme (TACE). ADAM17 is a type I integral
membrane zinc metalloproteinase, the catalytic domain of
which has been cocrystallised with the hydroxamic acid-
based inhibitor, Immunex compound 3, and the structure
solved at 2.0
 
˚ Ar e s o l u t i o n[ 67].
Like ADAM10, ADAM17 has been implicated in the
proteolysis of a large range of cell surface proteins of diverse
functions (reviewed in [68]). In relation to the cleavage of
APPthough,thebasalsheddingoftheproteinwasunaﬀected
in primary embryonic ﬁbroblasts derived from ADAM17
knockout mice whereas the phorbol ester regulated cleavage
was found to be deﬁcient [69, 70]. Similarly, the ADAM17
inhibitor, CP-661631, inhibited regulated but not constitu-
tive sAPPα secretion from human primary neuron cultures
without aﬀecting Aβ-peptide production [71]. In light of the
latter observation, it is perhaps of little surprise that it has
more recently been shown that ADAM10 and not ADAM17
or 9 is the physiologically relevant basal α-secretase activity
in primary neurons [72]. However, there is considerable
evidence to suggest that the enzyme is involved in basal
APP shedding in various other cell lines. Only constitutive
and not muscarine-regulated APP cleavage was enhanced in
HEK cells transfected with ADAM17 [73]. Similarly, Hiraoka
et al. [74] demonstrated that overexpression of ADAM17
in COS7 cells lead to a signiﬁcant increase in basal sAPPα
secretion. In contrast Asai et al. [75] used short interfering
RNAs (siRNAs) to deplete ADAM17 protein levels in human
glioblastoma A172 cells and subsequently demonstrated that
the proteinase was involved in both the constitutive and
regulated endogenous α-secretase processing of APP. Thus,
data derived from in vitro cell culture studies seem to
suggest that ADAM17 is generally involved in the regulated
processing of APP but that its involvement in constitutive
sAPPα production is somewhat more cell type-dependent.
Studies using synthetic peptide substrates oﬀer less
convincing proof that ADAM17 is involved in the α-
secretase processing of APP. Buxbaum et al. [76]r e p o r t e d
that recombinant ADAM17 cleaved a synthetic substrate
spanning the α-secretase cleavage site in APP at the Lys16-
Leu17 (Aβ-peptide numbering) bond. However, the authors
didnotpresentdatapertainingtothekineticsofthecleavage.
In contrast, Mohan et al. [77] examined the kinetics of
cleavage of a synthetic TNFα substrate by recombinant and
native ADAM17 and compared the cleavage to that of several
other proposed ADAM17 substrates, including APP. The
authors found that ADAM17 eﬃciently cleaved the TNFα
substrate but only cleaved the APP-derived peptide substrate
at high enzyme concentrations and extended reaction times
suggestingthatAPPmightbeapoorsubstratefortheenzyme
in vivo.
3.1.3. ADAM9 and ADAM15. The cDNA encoding the
zinc metalloproteinase ADAM9 (EC 3.4.24.B9) was isolated6 Biochemistry Research International
originally from a murine lung cDNA library [78]. Initially it
wasthoughtthattheenzymemightbedirectlyresponsible,at
least in part, for the α-secretase-mediated processing of APP.
The overexpression of both ADAM9 and APP in COS cells
led to an increase in the phorbol ester-regulated generation
of sAPPα [79]. The authors in this study did not, however,
determine the exact site of cleavage by ADAM9 leaving
open the possibility that the enzyme had a bond speciﬁcity
other than at the “regular” α-secretase cleavage site (Lys16-
Leu17). This latter point is certainly a possibility given the
fact that a soluble recombinant form of ADAM9 has been
shown to cleave a 12-mer synthetic peptide spanning the
APPα-secretasecleavagesiteattheHis14-Gln15bondwithin
the Aβ region [80]. However, a secreted form of ADAM9,
when coexpressed with APP in CHO cells, has been shown
to enhance phorbol ester-regulated APP cleavage at Lys16-
Leu17 [81].
Given the fact that promoter polymorphisms enhancing
ADAM9 transcription are protective against sporadic AD
[82], there does seem to be a connection between this zinc
metalloproteinase and the disease. However, research into
the possibility of a physiologically relevant direct cleavage
of APP by ADAM9 has all but petered out in recent
years. Instead, it now seems that ADAM9 inﬂuences APP
processing in an indirect manner via an eﬀect on ADAM10
as the transient overexpression of the former enzyme in
ADAM10
−/− ﬁbroblasts, in contrast to wild-type ﬁbroblasts,
had no eﬀect on sAPPα production [83]. More recently
it has been demonstrated in our laboratory that ADAM9
actually sheds ADAM10 from the cell surface [84] although
it remains unclear as to how this event would enhance α-
secretase shedding of APP as we also demonstrated that a
truncated soluble ADAM10 construct analogous to the shed
form of the enzyme did not enhance sAPPα production
despite being catalytically active against a synthetic peptide
substrate. Following this observation Tousseyn et al. [85]
demonstrated that both ADAM9 and ADAM15 are capable
ofsheddingADAM10andpresentedevidencesuggestingthat
the C-terminal membrane-associated ADAM10 fragment
generated following cleavage by ADAM9 could be further
processed to liberate an intracellular domain involved in
nuclear signaling. This latter observation opens the possibil-
ity that ADAM9-mediated ADAM10 nuclear signaling may
somehow enhance α-secretase cleavage of APP.
3.1.4. Other ADAMs as APP α-Secretases. Although it now
seems that ADAM10 is the physiologically relevant α-
secretase in primary neurons [72], a number of additional
ADAMs over and above ADAMs 9 and 17 have been impli-
cated in APP processing. Zou et al. [86] demonstrated that
ADAM33 (EC 3.4.24.-) could cleave a synthetic α-secretase
substrate but that cleavage occurred at His14-Gln15 rather
than Lys16-Leu17 and with quite low eﬃciency making it
unlikely that the enzyme is a physiologically relevant α-
secretase. In addition, Naus et al. [87] demonstrated that
ADAM8 (EC 3.4.24.-) could cleave APP in HEK cells with
a similar eﬃciency to that of ADAM10. Finally, Tanabe
et al. [88] demonstrated that overexpression of ADAM19
(EC 3.4.24.-) in A172 cells enhanced constitutive sAPPα
production and that siRNA depletion of the endogenous
enzyme decreased sAPPα production by approximately 21%.
H o w e v e r ,i tw o u l ds e e mt h a tA D A M 8a n dA D A M 1 9a r e ,
at best, responsible for a very minor fraction of sAPPα
generated in primary neurons given the major contribution
of ADAM10 in this respect [72].
3.2. Nardilysin: An ADAM Activating Zinc Metalloendopepti-
dase. Nardilysin (N-arginine dibasic convertase; NRDc; EC
3.4.24.61) is a member of the inverzincin/M16 family of zinc
metalloendopeptidases [89]. This family of enzymes have
in common an approximately 200-amino acid conserved
region containing the HXXEH binding motif of catalytic
Zn2+. NRDc has been shown to enhance the constitutive
shedding of sAPPα from COS7 cells transiently transfected
with APPWT,a ne ﬀect that was totally abolished by the
hydroxamic acid-based metalloproteinase inhibitor TAPI-2
[74]. It now appears that NRDc enhances ADAM9, -10, and
-17 activities regardless of the substrate being cleaved [90]
via a mechanism of action which remains unclear but which
does seem to involve a direct interaction of the proteins.
4. ZincMetalloproteinasesin
the Degradation of Aβ
Just as ADAMs can prevent Aβ generation in the ﬁrst
instance, the proteolytic degradation of preformed Aβ-
peptides represents another way by which to decrease the
steady-state levels of these potentially neurotoxic peptides in
the brain. Although proteinases from a number of diﬀerent
classes can degrade Aβ, by far the dominant class in this
respect is that of the zinc metalloproteinases.
4.1. Insulin Degrading Enzyme. The insulin degrading
enzyme (IDE) (EC 3.4.24.56) (insulysin, insulin protease) is
a 100–120kDa ubiquitously expressed zinc metallopeptidase
belonging to the M16A class of metalloendopeptidases
characterised by an inverted HXXEH motif in the active
site (as opposed to the HEXXH motif of other zinc
metalloproteinases). The enzyme is evolutionarily conserved
and possesses alternatively spliced and initiated variants
[91]. IDE cleaves a broad range of physiologically active
peptides including insulin, glucagon, and atrial natriuretic
factor with its main physiological function being to regulate
steady-state levels of peripheral insulin [92]. The structure of
IDE resembles a clam shape consisting of four homologous
domains, and the enzyme is dependent on an ATP-powered
structural regulatory switch in order to permit substrate
access to the active site [91].
As far as cleaving Aβ is concerned, IDE degrades Aβ in
conditioned medium from neuronal cultures [93], and both
ratandmouseIDEknockoutanimalsexhibitenhancedbrain
Aβ levels [94, 95]. Conversely, the overexpression of IDE in
transgenic mice results in drastically reduced brain Aβ levels
and decreased plaque formation along with reduced AD-like
cytopathology [96]. In addition to cleaving Aβ,i th a sb e e n
suggested that IDE might also cleave the APP intracellularBiochemistry Research International 7
domain as evidenced by increased AICD levels in the brains
of IDE knockout mice [97]. However, the treatment of cell
cultures with IDE inhibitors did not enhance AICD levels
[98] suggesting that the direct cleavage of the fragment by
IDE alone might not account for the enhanced AICD levels
observed in IDE knockout animals.
In AD-aﬄicted human brain, IDE is associated with
senile plaques and Aβ deposits in microvessels [99, 100], and
hippocampal levels of the enzyme are reduced in patients
considered to be at high risk of developing AD [101]. At
the genetic level, the risk of developing AD has been linked
to variation within a 276Kb region of chromosome 10
encoding, interalia, IDE [102]. Furthermore, decreased IDE
catalytic activity but not expression was detected in the
lymphoblasts of chromosome 10-linked AD family members
[103].
4.2. Neutral Endopeptidase. Neutral endopeptidase (NEP)
(EC. 3.4.24.11) (neprilysin, enkephalinase, endopeptidase
24.11, kidney brush border neutral proteinase, common
acute lymphoblastic leukaemia antigen, and CD10) is an
85–93kDa type II membrane protein belonging to the
M13 class of zinc metalloendopeptidases [104]. The protein
consists of a short N-terminal cytosolic region, a single
transmembrane helix, and a large C-terminal ectodomain
containing, interalia, the catalytic site with a conserved
HEXXH motif participating in zinc coordination [91]. NEP
exhibits an extensive substrate speciﬁcity cleaving many
biologically active peptides including substance P, neu-
ropeptide Y, enkephalin, and cholecystokinin; the enzyme,
therefore, has extensive roles in neuropeptide signaling and
the regulation of vascular tone [104].
T h ef a c tt h a tN E Pm i g h tb ei n v o l v e di nA β degradation
originally came to light when it was established that the
enzyme could cleave Aβ, but not full-length APP, in vitro
[105]. However, it took a further ﬁve years to establish
that NEP was involved in the in vivo degradation of Aβ
when Iwata et al. [106] injected radioactive Aβ-peptides into
rat brain and observed that their subsequent degradation
was inhibited by compounds such as phosphoramidon and
thiorphan. It was subsequently shown that NEP knockout
mice exhibited signiﬁcantly elevated levels of Aβ in their
brains [107] and that, when APP transgenic mice were
crossed with NEP-deﬁcient animals, the resultant progeny
exhibited impaired hippocampal synaptic plasticity and
increased cognitive decline compared to APP transgenics
with normal levels of NEP [108].
In human postmortem brain samples an increased
amyloid plaque density is associated with decreased NEP
immunoreactivity [109], and, in the brains of AD patients,
NEP mRNA levels in the hippocampus and temporal gyrus
were lower than those in the same regions of control brains
[110]. Furthermore, an age-dependant decline in NEP levels
has been demonstrated in both normal and AD brains [111].
At the genetic level, at least two single nucleotide
polymorphisms (SNPs) located within introns of the NEP
gene have been positively associated with AD [112], and
an NEP GT-repeat polymorphism is also associated with
the late-onset form of the disease [113]. Finally, reduced
NEP expression in AD is associated with an APOE ε4
genotype which itself is a major risk factor for sporadic AD
[114].
4.3. Endothelin Converting Enzymes 1 and 2. Endothelin
converting enzymes (ECEs) (EC. 3.4.24.71) are members
of the M13 group of proteins (type II integral mem-
brane proteins with zinc metalloproteinase activity) and
display several sequence and domain structure similarities
to another member of this family, NEP (Section 4.2).
ECEs cleave biologically inactive big endothelins to generate
mature endothelins which act as vasoconstrictors [115].
ThreeisoformsofECEshavebeenreported,ECE-1,ECE-
2, and ECE-3, but only the former two have been implicated
in Aβ degradation. Four alternative splice variants of ECE-
1, localized both at the cell membrane and intracellularly,
have been reported in humans (ECE-1a, ECE-1b, ECE-1c,
and ECE-1d) [116, 117]. In contrast, ECE-2 is localized
almost exclusively to the trans-Golgi network [115]. Eckman
et al. [118] initially demonstrated that the metalloproteinase
inhibitor phosphoramidon enhanced extracellular levels of
Aβ in cultured cells through an inhibition of peptide degra-
dation. The authors also showed that the overexpression of
ECE-1 in CHO cells resulted in a 90% reduction of Aβ levels
and that recombinant ECE-1 was capable of cleaving Aβ
at multiple sites. The same group subsequently reported a
signiﬁcant increase in Aβ levels in the brains of ECE-1 and
ECE-2 knockout mice [119] and also demonstrated even
greater Aβ accumulation in the brains of combined ECE-1
and NEP knockout mice suggesting that both enzymes act in
unison to degrade Aβ [120]. Interestingly, both ECE-1 and
E C E - 2m R N Al e v e l sw e r ee n h a n c e dw h e nc e l lc u l t u r e sw e r e
treated with Aβ suggesting the existence of a feedback loop
mechanism whereby increases in Aβ levels enhance its own
degradation [121, 122].
At the genetic level, Funalot et al. [123] identiﬁed a
C338A polymorphism in the regulatory region of the ECE-
1b gene that was associated with increased transcriptional
activity. Theauthorsdemonstratedthatindividuals homozy-
gous for the A allele were at a reduced risk of developing
AD. An additional study also revealed a protective role for
the A allele within a cohort of Chinese subjects [121].
Furthermore, using microarray technology, Weeraratna et al.
[124] observed that the most signiﬁcantly down regulated
gene in AD was that of ECE-2. The authors also presented
immunohistochemical evidence demonstrating a reduction
in ECE-2 protein expression in inferior parietal lobe tissue
from AD brain.
4.4. Angiotensin Converting Enzyme. The angiotensin con-
verting enzyme (ACE) (EC 3.4.15.1) is a type I integral
membrane zinc-dependent dipeptidase that cleaves two
vasoactive peptides, angiotensin I and bradykinin [125,
126]. Consequently, the enzyme plays an important role in
the regulation of hypertension and in the development of
vascular pathology and endothelium remodelling in some
disease states [127, 128]. There are two distinct isoforms of8 Biochemistry Research International
mammalian ACE, somatic (sACE) and testis (tACE), both of
which are transcribed from a single gene by the use of two
alternativepromoters[129].SomaticACE(180kDa)consists
of two identical catalytic domains (C- and N-domains),
bothbearingafunctionalzinc-dependentactivesite,whereas
testis ACE consists of only a single domain corresponding to
the C-terminal domain of sACE [128].
Of all the zinc metalloproteinases involved in Aβ degra-
dation, there is perhaps most controversy surrounding ACE.
The enzyme was originally shown to degrade Aβ in vitro
cleaving the Asp7-Ser8 and Arg5-His6 peptide bonds [130],
and, more recently, the Aβ degrading activity of ACE has
been reported to be located speciﬁcally within the protein’s
N-domain [131]. One study reported a signiﬁcant elevation
of Aβ levels in the brains of mice treated with the ACE
inhibitor, captopril [132]. Furthermore, the ACE inhibitor,
perindopril, has recently been shown to improve cognitive
performance in APP/presenilin-1 transgenic mice injected
with Aβ [133]. However, for every study reporting a role of
ACE in the prevention of AD, there is at least one other that
presents negative date in this regard. For example, there are
several studies which, using genetic or chemical inactivation
of ACE in vivo, suggest that the enzyme does not have a
substantialphysiologicalroletoplayinthedegradationofAβ
[106,120,134].Inthisrespectitisnotablethatanotherofthe
physiological substrates of ACE, angiotensin I, is converted
to the potent vasoconstrictor ACE II. Consequently, both
substrate and product are ligands for subtypes of androgen
receptors, the regulation of which has also been implicated
in AD [135]. The question arises, therefore, as to whether the
eﬀect of ACE inhibitors on Aβ levels is due to the inhibition
of the enzyme’s Aβ degrading activity or to alterations in the
relative levels of angiotensins I and II and their abilities to
interact with their cognate receptors.
4.5. Matrix Metalloproteinases. Matrix metalloproteinases
(MMPs) are zinc-dependent endopeptidases belonging to
the metzincin superfamily and are predominantly extra-
cellular enzymes capable of cleaving a wide range of
extracellular matrix proteins and bioactive peptides [136].
MMP-2 (EC 3.4.24.24), MMP-3 (EC 3.4.24.B6), and MMP-
9 (EC. 3.4.24.35) have all been shown to possess Aβ-
degrading activity in vitro; however, unlike ECE-1, NEP,
and IDE, MMP-9 is capable of cleaving aggregated Aβ
ﬁbrils [137]. Furthermore, signiﬁcant elevations in Aβ have
been reported in the brains of both MMP-2 and MMP-9
knockout mice [138]. Although basal expression levels of
MMPs are low in the brain, several cell types (glial, neuronal,
and vascular) upregulate endogenous MMP-2, -3, and -9
expression in response to Aβ treatment [139–141]. However,
the expression levels and activities of these three enzymes
appeared not to diﬀer signiﬁcantly between AD and control
b r a i n sa n dw e r en o tr e l a t e dt oA β plaque load [142]. At the
genetic level, the analysis of polymorphisms in the MMP-3
(-1171 5A/6A) and MMP-9 (C-156T) genes indicated that
the -1171 6A MMP-3 allele (which was associated with
reduced promoter activity) was associated with AD whereas
the MMP-9 polymorphism was not [142].
4.6. Other Aβ Degrading Zinc Metalloproteinases. Aβ is
clearly subject to proteolysis by a range of zinc metallopro-
teinases as discussed in the preceding sections of this paper.
Furthermore, it should be noted that new candidate enzymes
in this respect are still coming to light. For example, it has
recently been reported that glutamate carboxypeptidase II
(GCPII) (EC 3.4.17.21), a zinc metalloproteinase expressed
in multiple tissues including the brain [143], was capable
of cleaving Aβ monomers at their C-termini to produce a
rangeofsmallerfragmentsalongwithAβ1-14thatlackedthe
aggregation potential and cellular toxicity of full-length Aβ.
The authors also demonstrated that GCPII could degrade
soluble Aβ oligomers and ﬁbrils and could reduce plaque
size in the brains of APP-presenilin1ΔE9 transgenic mice.
Furthermore, in cell cultures, the overexpression of GCPII
reduced the levels of secreted or exogenously supplemented
Aβ-peptides. In addition to GCPII the ability of ADAMs, be
it in their shed or membrane-associated forms, to degrade
Aβ as opposed to their normal full-length APP substrate,
remains to be established.
5. Concluding Remarks
Proteolytic enzymes play a central role in AD. Whilst it is
the aspartyl proteinase class that contributes directly to the
formation of neurotoxic Aβ via the amyloidogenic pathway,
it is undoubtedly the zinc metalloproteinases that play the
most signiﬁcant roles both in the preclusion of Aβ formation
via the nonamyloidogenic pathway and in the degradation of
these peptides (Figure 4). Whilst much research in the AD
ﬁeld continues to focus on the development of inhibitors of
the amyloidogenic pathway, it is clear that the upregulation
of various zinc metalloproteinase activities represents a
possible alternative therapeutic strategy for the treatment of
the disease.
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